BTIG analyst Julian Harrison reiterated a Neutral rating on Aclaris Therapeutis (NASDAQ: ACRS).The analyst comments "Aclaris has dosed the first ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE